Commercial Use

Why Now: BH3 Mimetic Era Demands Functional Companion Diagnostics

Market Timing

BH3 mimetics and emerging MCL-1–targeted agents demonstrate powerful but heterogeneous responses in AML and multiple myeloma, with rapid emergence of resistance mechanisms that confound treatment planning.

Current genomic and single-protein markers incompletely capture the dynamic state of mitochondrial priming, leaving pharmaceutical partners and clinicians without scalable functional companion diagnostics for these high-value drug classes.

BH3 Mimetic Market
Projected global market by 2030

$ 0 B
Pipeline Agents
MCL-1 and BCL-xL inhibitors in development
0 +
Approved CDx
No functional biomarkers currently available
0 +

PRIMABS™-Dx Value Proposition

xx

Functional Mechanism Readout

Uniquely measures the final common pathway of many cancer drugs—mitochondrial priming—rather than relying solely on upstream genetic alterations that may not predict functional response.

zz

Clinically Scalable Platform

Delivers assays compatible with standard clinical workflows that derisk trials, enrich responder populations, and enable real-time pharmacodynamic monitoring in routine patient samples.

Drug Development Integration

Accelerates companion diagnostic development timelines and regulatory pathways through mechanistically grounded, biologically validated biomarker algorithms tailored to specific agents.